Your Health, We Care
Deucravacitinib is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Limitations of Use:
Deucravacitinib is not recommended for use in combination with other potent immunosuppressants.
from FDA，2022.09
Deucravacitinib is suitable for treating plaque psoriasis.【more】
Release date：2026-01-05Recommended：17
LuciusVersionofDeucravacitinib:DosageandAdministration,Indications,PrecautionsIn···【more】
Release date：2025-12-18Recommended：52
